Jazz Pharmaceuticals (JAZZ)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$241.31+0.52%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Warn: Primary pillar under pressure — Revenue growth of at least 6% per year: Q2 FY26 rev +16.0% vs 6% target.
Jazz Pharmaceuticals grows revenue about 19% year over year. Profit margins are strong near 90%. Cash from operations rose sharply to $408 million. The company advances its pipeline with new drug launches and partnerships.
Pipeline setbacks and trial failures threaten future growth. Revenue growth may slow below 6%. Guidance cuts and rating downgrades raise concerns about execution.
The price is about 5% above our fair value near $236. Analysts expect 6% revenue growth. Our view is slightly more cautious on growth and pipeline progress.
Breaks if: cash from operations falls below $300 million next year
Breaks if: gross margin falls below 85% in FY26
Breaks if: Major pipeline setbacks or launch failures occur in 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on growth through pipeline advancements and acquisitions. The current thesis state is intact, supported by strong recent financial performance.
The market currently prices JAZZ as relatively cheap compared to its peers, with a slight expectations gap. This suggests that investors are not overly optimistic about future performance, allowing room for potential positive surprises.
Fundamentals are likely to continue improving, driven by strong revenue growth and active pipeline management. However, there is a moderate risk of missing earnings expectations due to the high-miss-rate nature of the industry.
The thesis hinges on management's ability to advance its pipeline and maintain revenue growth while navigating sector dynamics. Key factors include the performance of sector bellwethers and any changes in guidance that could impact credibility.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The company reported a strong earnings beat. This beat supports a stronger revenue growth outlook. Positive Phase 3 trial results for Ziihera also improved investor sentiment. The approval expands treatment options for the oncology portfolio. The market may have already priced in some of this news.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: YoY revenue growth falls below 6% next year
Over the next 1 to 3 years, JAZZ's performance will depend on its execution and external market conditions. Not investment advice.